Information on EC 1.13.11.34 - arachidonate 5-lipoxygenase and Organism(s) Homo sapiens

for references in articles please use BRENDA:EC1.13.11.34
Word Map on EC 1.13.11.34
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Select one or more organisms in this record:
This record set is specific for:
Homo sapiens
Show additional data
Do not include text mining results
Include (text mining) results
Include results (AMENDA + additional results, but less precise)


The taxonomic range for the selected organisms is: Homo sapiens

The enzyme appears in selected viruses and cellular organisms

EC NUMBER
COMMENTARY hide
1.13.11.34
-
RECOMMENDED NAME
GeneOntology No.
arachidonate 5-lipoxygenase
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
arachidonate + O2 = (6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyicosa-6,8,11,14-tetraenoate
show the reaction diagram
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
dioxygenation
-
-
-
-
oxidation
redox reaction
-
-
-
-
reduction
-
-
-
-
PATHWAY
BRENDA Link
KEGG Link
MetaCyc Link
lipoxin biosynthesis
-
-
arachidonic acid metabolism
-
-
Arachidonic acid metabolism
-
-
Metabolic pathways
-
-
SYSTEMATIC NAME
IUBMB Comments
arachidonate:oxygen 5-oxidoreductase
-
CAS REGISTRY NUMBER
COMMENTARY hide
80619-02-9
-
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
malfunction
metabolism
physiological function
additional information
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
(5S,6E,8Z,11Z,14Z)-5-hydroperoxyicosa-6,8,11,14-tetraenoate
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
show the reaction diagram
-
epoxidation
-
-
?
(5Z,8Z,10E,12S,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoic acid + O2
?
show the reaction diagram
-
-
-
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
show the reaction diagram
2',7'-dichlorodihydrofluorescein diacetate + O2
?
show the reaction diagram
-
development of a fluorescence assay for 5-LOX, overview
-
-
?
5,8,11,14,17-eicosapentaenoic acid + O2
?
show the reaction diagram
-
-
-
-
?
5-hydroperoxyeicosatetraenoic acid
leukotriene A4 + H2O
show the reaction diagram
-
-
is unstable and metabolized to leukotriene B4
-
?
7,7-d2-arachidonate + O2
7,7-d2-(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
show the reaction diagram
-
analysis of the product distribution reveals that 5-LOX displays a reversal of selectivity to bypass abstracting the deuterium atom from C7
-
-
?
8,11,14-eicosatrienoic acid + O2
?
show the reaction diagram
-
4% of the activity with 5,8,11,14,17-eicosapentaenoic acid
-
-
?
arachidonate + O2
(5S,6E,8Z,11Z,14Z)-5-hydroperoxyicosa-6,8,11,14-tetraenoate
show the reaction diagram
arachidonate + O2
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
show the reaction diagram
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyicosa-6,8,11,14-tetraenoate
show the reaction diagram
-
-
-
-
?
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
show the reaction diagram
arachidonic acid + O2
(5S,6E,8Z,11Z,14Z)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
show the reaction diagram
-
-
-
-
?
arachidonic acid + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
show the reaction diagram
arachidonic acid + O2
5-hydroperoxyeicosatetraenoic acid
show the reaction diagram
-
-
-
-
?
additional information
?
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
(5S,6E,8Z,11Z,14Z)-5-hydroperoxyicosa-6,8,11,14-tetraenoate
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
show the reaction diagram
-
epoxidation
-
-
?
(5Z,8Z,10E,12S,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoic acid + O2
?
show the reaction diagram
-
-
-
-
?
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
leukotriene A4 + H2O
show the reaction diagram
5-hydroperoxyeicosatetraenoic acid
leukotriene A4 + H2O
show the reaction diagram
-
-
is unstable and metabolized to leukotriene B4
-
?
arachidonate + O2
(5S,6E,8Z,11Z,14Z)-5-hydroperoxyicosa-6,8,11,14-tetraenoate
show the reaction diagram
arachidonate + O2
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate + H2O
show the reaction diagram
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-hydroperoxyicosa-6,8,11,14-tetraenoate
show the reaction diagram
-
-
-
-
?
arachidonic acid + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyeicosa-6,8,11,14-tetraenoate
show the reaction diagram
arachidonic acid + O2
5-hydroperoxyeicosatetraenoic acid
show the reaction diagram
-
-
-
-
?
additional information
?
-
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
1-Oleoyl-2-acetyl-sn-glycerol
-
both Ca2+ and glyceride, e.g. 1-oleoyl-2-acetyl-sn-glycerol, might decrease the concentration of lipid hydroperoxide needed for activation of 5-LO, enabling cellular 5-LO product formation at a low redox tone
Fe3+
-
because catalysis by 5-LO requires oxidation of Fe2+ to the active Fe3+ state by lipid hydroperoxides, the redox tone is an important parameter of cellular 5-LO activity
Iron
-
wild-type enzyme contains 0.65 mol of iron per mol of enzyme, H372 and H550 constitute two of the iron ligands
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(-)-epicatechin
-
-
(2,4-dihydroxyphenyl)[3-(1-[hydroxy[(3,4,5-trihydroxyphenyl)methyl]amino]ethyl)phenyl]methanone
-
-
(2,4-dihydroxyphenyl)[3-(1-[hydroxy[(4-hydroxyphenyl)methyl]amino]ethyl)phenyl]methanone
-
-
(2E,2'E)-(1,1'-(2,2-bis((4-(((E)-3-(3,4-dihydroxyphenyl)acryloyloxy)methyl)-1H-1,2,3-triazol-1-yl)methyl)propane-1,3-diyl)bis(1H-1,2,3-triazole-4,1-diyl))bis(methylene) bis(3-(3,4-dihydroxyphenyl)acrylate)
-
potent inhibition by 92%
(2E,2'E)-(1,1'-(2,2-bis((4-(cinnamoyloxymethyl)-1H-1,2,3-triazol-1-yl)methyl)propane-1,3-diyl)bis(1H-1,2,3-triazole-4,1-diyl))bis(methylene) bis(3-phenylacrylate)
-
shows less inhibitory activity than the corresponding clusters bearing the caffeic acid moiety
(2E,2'E)-(1,1'-(2-((4-(((E)-3-(3,4-dihydroxyphenyl)acryloyloxy)methyl)-1H-1,2,3-triazol-1-yl)methyl)-2-(hydroxymethyl)propane-1,3-diyl)bis(1H-1,2,3-triazole-4,1-diyl))bis(methylene) bis(3-(3,4-dihydroxyphenyl)acrylate)
-
potent inhibition by 91%
(2E,2'E)-(1,1'-(2-((4-(cinnamoyloxymethyl)-1H-1,2,3-triazol-1-yl)methyl)-2-(hydroxymethyl)propane-1,3-diyl)bis(1H-1,2,3-triazole-4,1-diyl))bis(methylene) bis(3-phenylacrylate)
-
shows less inhibitory activity than the corresponding clusters bearing the caffeic acid moiety
(2E,2'E)-2,2'-(4,4'-(2,2-bis(((1-(2-((E)-3-(3,4-dihydroxyphenyl)acryloyloxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)methyl)propane-1,3-diyl)bis(oxy)bis(methylene)bis(1H-1,2,3-triazole-4,1-diyl))bis(ethane-2,1-diyl) bis(3-(3,4-dihydroxyphenyl)acrylate)
-
-
(2E,2'E)-2,2'-(4,4'-(2,2-bis(((1-(2-(cinnamoyloxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)methyl)propane-1,3-diyl)bis(oxy)bis(methylene)bis(1H-1,2,3-triazole-4,1-diyl))bis(ethane-2,1-diyl) bis(3-phenylacrylate)
-
shows less inhibitory activity than the corresponding clusters bearing the caffeic acid moiety
(2E,5E)-5-[(2E)-3-(furan-2-yl)prop-2-en-1-ylidene]-3-phenyl-2-(phenylimino)-1,3-thiazolidin-4-one
-
-
(5E)-2-(3-acetylphenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
-
-
(5E)-2-(3-fluorophenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
-
-
(5E)-2-(4-acetylphenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
-
-
(5E)-2-(4-aminophenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
-
-
(5E)-2-(4-chlorophenyl)-5-(4-hydroxybenzylidene)-1,3-thiazol-4(5H)-one
-
-
(5E)-2-(4-chlorophenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
-
-
(5E)-2-(4-hydroxyphenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
-
-
(5E)-2-(4-methylphenyl)-5-(3,4,5-trimethoxybenzylidene)-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(2,4-dimethoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(2-hydroxy-3-methoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(2-hydroxy-3-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(3,5-dimethoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(3-chloro-4-hydroxy-5-methoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(3-chloro-4-hydroxy-5-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(3-chloro-5-ethoxy-4-hydroxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(3-chlorobenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(4-hydroxy-3-methoxy-5-nitrobenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(4-methoxybenzylidene)-2-(4-methoxyphenyl)-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(4-methoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(4-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(4-tert-butylbenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(4-[(methylperoxy)acetyl]benzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(5-chloro-2-hydroxy-3-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
-
-
(5E)-5-(anthracen-9-ylmethylidene)-2-phenyl-1,3-thiazol-4(5H)-one
-
-
(5E)-5-4-[(methylperoxy)acetyl]benzylidene
-
-
(5E)-5-benzylidene-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
-
-
(5E)-5-[4-(dimethylamino)benzylidene]-2-(piperidin-1-yl)-1,3-thiazol-4(5H)-one
-
-
(5S,6S,7E,9E,11Z,14Z)-5,6-epoxyicosa-7,9,11,14-tetraenoate
-
product inhibition
(5Z)-2-(cyclohexylamino)-5-(4-propoxybenzylidene)-1,3-thiazol-4(5H)-one
-
-
(5Z)-5-(4-methoxybenzylidene)-2-(pyrrolidin-1-yl)-1,3-thiazol-4(5H)-one
-
-
(5Z)-5-(4-methylbenzylidene)-2-(naphthalen-2-ylamino)-1,3-thiazol-4(5H)-one
-
-
(5Z)-5-benzylidene-2-(phenylamino)-1,3-thiazol-4(5H)-one
-
-
(E)-N-hydroxy-N-(3-(3-phenoxyphenyl)-allyl)acetamide
-
BWA4C
([4-chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl]sulfanyl)(naphthalen-1-yl)acetic acid
-
-
1-(2,4-difluorophenyl)-3-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)urea
-
-
1-(2,4-dihydroxyphenyl)-2-(naphthalen-2-yl)ethanone
-
-
1-(3-[5-(hydroxyureido)methyl-2-methoxyphenoxy]propyl)-3-[4-(trifluoromethoxy)phenyl]urea
-
KM55, a multitarget ligand and dual 5-lipoxygenase (5-LO)/soluble epoxide hydrolase (sEH) inhibitor. KM55 potently inhibits both enzymes in vitro and attenuates the formation of leukotrienes in human whole blood. It significantly inhibits the LPS-induced adhesion of leukocytes to endothelial cells by blocking leukocyte activation. Compound synthesis and evaluation, overview. KM55 inhibits the formation of leukotriene B4 and 5-hydroxyeicosatrienoic acid, while the formation of 12-hydroperoxyicosatetraenoate and 15-hydroperoxyicosatetraenoate are unaffected. KM55 blocks leukocyte-endothelial cell interaction by impairing leukocyte activation, whereas endothelial cells are not affected
1-benzyl-3-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)urea
-
-
1-O-dodecyl 2,3-O-isopropylidene-5,6-dideoxy-5-N-[4-(2-hydroxy-2-oxoethyl) phenylaminocarbonyl] amino-beta-L-gulofuranoside sodium salt
-
competitive inhibitior, IC50: 0.0035 mM with recombinant enzyme, IC50: 0.005 mM with native enzyme
1-[3-(methylsulfanyl)phenyl]-3-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)urea
-
-
10,17(S)-dihydroxydocosahexaenoic acid
-
IC50: 0.017 mM
11alpha,13-dihydrohelenalin acetate
-
enzyme from polymorphonuclear leukocyte
15-hydroperoxy-6,8,11,13-eicosatetraenoic acid
-
IC50: 0.0048 mM
2,3-dichlorophenyl 3,5-dinitrobenzoate
-
-
2,5-dimethoxy-3-tridecylbenzene-1,4-diol
-
-
2-(2,2-dimethyl-6-(4-nitrophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)acetic acid
-
-
2-(2,2-dimethyl-7-phenyl-6-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrrolizin-5-yl)acetic acid
-
-
2-(2-methoxyphenyl)-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)acetamide
-
-
2-(3-acetylphenyl)propanoic acid
-
-
2-(3-benzoylphenyl)propanoic acid
-
-
-
2-(3-phenoxyphenyl)propanoic acid
-
-
2-(4-(biphenyl-4-ylamino)-6-chloropyrimidine-2-ylthio)octanoic acid
-
-
2-(4-(biphenyl-4-ylmethylamino)-6-chloropyrimidin-2-ylthio)octanoic acid
-
-
2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)acetic acid
-
-
2-(4-chloro-6-(4'-cyanobiphenyl-4-ylamino)pyrimidin-2-ylthio)octanoic acid
-
-
2-(4-chloro-6-(5-methoxy-2-methylbiphenyl-4-ylamino)pyrimidin-2-ylthio)octanoic acid
-
-
2-(4-methylphenyl)-5-(2-phenylethenylidene)-1,3-thiazol-4(5H)-one
-
-
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-(5-methyl-1,3-thiazol-2-yl)propanamide
-
-
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-1,3-thiazol-2-ylpropanamide
-
-
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-pyridin-2-ylpropanamide
-
-
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-thiophen-3-ylpropanamide
-
-
2-(6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)-N-(methylsulfonyl)acetamide
-
-
2-(6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)-N-(phenylsulfonyl)acetamide
-
-
2-(6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)-N-tosylacetamide
-
-
2-(6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1Hpyrrolizin-5-yl)-N-tosylpropanamide
-
-
2-(6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)acetic acid
-
-
2-(6-(4-tert-butylphenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)acetic acid
-
-
2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)-N-(thiophen-2-ylmethyl)propanamide
-
-
2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)-N-1,3-thiazol-2-ylpropanamide
-
-
2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)-N-pyridin-2-ylpropanamide
-
-
2-(dibenzo[b,d]furan-3-yl)-5-hydroxycyclohexa-2,5-diene-1,4-dione
-
-
2-([4-chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl]sulfanyl)octanoic acid
-
-
2-benzyl-5-hydroxycyclohexa-2,5-diene-1,4-dione
-
-
2-hexyl-5-hydroxycyclohexa-2,5-diene-1,4-dione
-
-
2-hydroxy-5-(3-nitrophenyl)cyclohexa-2,5-diene-1,4-dione
-
-
2-hydroxy-5-(naphthalen-2-ylmethyl)cyclohexa-2,5-diene-1,4-dione
-
-
2-hydroxy-5-methoxy-3-(naphthalen-2-ylmethyl)cyclohexa-2,5-diene-1,4-dione
-
-
2-methoxy-5-(naphthalen-2-yloxy)cyclohexa-2,5-diene-1,4-dione
-
-
2-methyl-3-[(morpholine-4-carbonyl)amino]-3-oxopropanoic acid
-
-
2-[(4-[[3,5-bis(2,2,2-trifluoroethoxy)phenyl]amino]-6-chloropyrimidin-2-yl)sulfanyl]octanoic acid
-
-
2-[2-[(2-methyl-1H-benzimidazol-1-yl)methyl]phenoxy]acetamide
-
a BRP-7 derivative
2-[2-[(2-[1-[4-(2-methylpropyl)phenyl]ethyl]-1H-benzimidazol-1-yl)methyl]phenoxy]acetamide
-
a BRP-7 derivative
2-[3-(2-methylpropanoyl)phenyl]propanoic acid
-
-
2-[3-(morpholine-4-carbonyl)phenyl]propanoic acid
-
-
2-[3-[(4-hydroxyphenyl)carbamoyl]phenyl]propanoic acid
-
-
2-[3-[hydroxy(phenyl)amino]phenyl]propanoic acid
-
-
2-[4'-(iso-propylphenyl)-amino]-5,6-dimethyl-1,4-benzoquinone
-
potent inhibitor, IC50: 0.006 mM
2-[4'-[(morpholin-4-yl)sulfanyl][1,1'-biphenyl]-3-yl]propanoic acid
-
-
2-[4-(morpholine-4-carbonyl)phenyl]propanoic acid
-
-
2-[4-([[(2E)-3-phenylprop-2-enoyl]oxy]methyl)-1H-1,2,3-triazol-1-yl]ethyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
-
-
2-[5,8-dimethyl-7-(2-morpholin-4-ylethoxy)-1,2,3,4-tetrahydronaphthalen-2-yl]-N-1,3-thiazol-2-ylpropanamide
-
-
2-[6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl]acetic acid
-
-
2-[7-[2-(dimethylamino)ethoxy]-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl]-N-1,3-thiazol-2-ylpropanamide
-
-
2-[7-[2-(dimethylamino)ethoxy]-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl]-N-pyridin-2-ylpropanamide
-
-
3'-nitrobiphenyl-2,4-diol
-
-
3,4,5-trimethoxy-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)benzamide
-
-
3,4,6-trimethoxy-5-undecylcyclohexa-2,4-dien-1-one
-
-
3-((naphthalene-1-yloxy)carbonyl)benzoic acid
-
-
3-(1,10-dihydroxydecyl)-2,5-dimethoxycyclohexa-2,5-diene-1,4-dione
-
-
3-(1-acetoxy-10-hydroxydecyl)-2,5-dimethoxycyclohexa-2,5-diene-1,4-dione
-
-
3-(1-carboxyethyl)benzoic acid
-
-
3-(10-hydroxydecyl)-2,5-dimethoxycyclohexa-2,5-diene-1,4-dione
-
-
3-(10-hydroxydecyl)-4,5-dimethoxycyclohexa-3,5-diene-1,2-dione
-
-
3-(11-hydroxyundecyl)-2,5-dimethoxycyclohexa-2,5-diene-1,4-dione
-
-
3-(11-hydroxyundecyl)-4,5-dimethoxycyclohexa-3,5-diene-1,2-dione
-
-
3-(6-(4-chlorphenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)propionic acid
-
-
3-(8-hydroxyoctyl)-2,5-dimethoxycyclohexa-2,5-diene-1,4-dione
-
-
3-(8-hydroxyoctyl)-4,5-dimethoxycyclohexa-3,5-diene-1,2-dione
-
-
3-(benzyloxycarbonyl)benzoic acid
-
-
3-(cyclohexylmethyl)-2,5-dihydroxycyclohexa-2,5-diene-1,4-dione
-
-
3-(decahydronaphthalen-2-ylmethyl)-2,5-dihydroxycyclohexa-2,5-diene-1,4-dione
-
-
3-(naphhthalen-1-ylcarbmoyl)benzoic acid
-
-
3-(phenylcarbamoyl)benzoic acid
-
-
3-benzyl-2-hydroxy-5-methoxycyclohexa-2,5-diene-1,4-dione
-
-
3-dodecyl-4,5-dimethoxybenzene-1,2-diol
-
-
3-dodecyl-4,5-dimethoxycyclohexa-3,5-diene-1,2-dione
-
-
3-propylphenyl 3,5-dinitrobenzoate
-
-
3-tolyl 3,5-dinitrobenzoate
-
-
3-tridecyl-4,5-dimethoxybenzene-1,2-diol
-
shows anti-inflammatory effectiveness
3-undecyl-4,5-dimethoxybenzene-1,2-diol
-
-
4,5-dimethoxy-3-tridecylcyclohexa-3,5-diene-1,2-dione
-
shows anti-inflammatory effectiveness
4,5-dimethoxy-3-undecylcyclohexa-3,5-diene-1,2-dione
-
-
4-(1-benzothiophen-3-yl)benzene-1,3-diol
-
-
4-(4-(4-chlorophenyl)thiazol-2-ylimino)cyclohexa-2,5-dienone
-
ST-1905
-
4-(4-chlorophenyl)-7-([3-fluoro-5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]sulfanyl)-2H-chromen-2-one
-
IC50: 180 nM
4-(4-fluorophenyl)-7-([3-fluoro-5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenoxy]methyl)-2H-chromen-2-one
-
IC50: 55 nM
4-(4-fluorophenyl)-7-([3-fluoro-5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]sulfanyl)-2H-chromen-2-one
-
IC50: 27 nM
4-(dibenzo[b,d]furan-3-yl)benzene-1,3-diol
-
-
4-(naphthalen-2-ylmethyl)benzene-1,3-diol
-
-
4-(thianthren-2-yl)benzene-1,3-diol
-
-
4-benzylbenzene-1,3-diol
-
-
4-chloro-N-([4-[(2E)-3-(2,4-dichlorophenyl)prop-2-enoyl]phenyl]carbamoyl)benzenesulfonamide
-
IC50: 0.00042 mM
4-chloro-N-([4-[(2E)-3-phenylprop-2-enoyl]phenyl]carbamoyl)benzenesulfonamide
-
IC50: 0.00083 mM
4-hexylbenzene-1,3-diol
-
-
4-methoxy-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)benzamide
-
-
4-methyl-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)-1,2,3-thiadiazole-5-carboxamide
-
-
4-methyl-N-([4-[(2E)-3-(2,3,4-trimethylphenyl)prop-2 enoyl]phenyl]carbamoyl)benzenesulfonamide
-
IC50: 0.00045 mM
4-methyl-N-([4-[(2E)-3-phenylprop-2-enoyl]phenyl]carbamoyl)benzenesulfonamide
-
IC50: 0.00089 mM
4-[(4-cyclohexyl-5-methyl-1,3-thiazol-2-yl)amino]-2,6-dimethylphenol
-
lead compound, in vitro pharmacokinetic profile, shows no cytotoxicity, overview
4-[(hydroxy[1-[3'-(morpholin-4-yl)[1,1'-biphenyl]-3-yl]ethyl]amino)methyl]phenol
-
-
4-[5-(1H-indol-3-yl)-3-trifluoromethyl-4,5-dihydropyrazol-1-yl]-benzenesulfonamide
-
0.01 mM inhibits LOX-5 by 41%
4-[5-(6-chloro-1H-indol-3-yl)-3-trifluoromethyl-4,5-dihydropyrazol-1-yl]-benzenesulfonamide
-
0.01 mM inhibits LOX-5 by 51%
4-[5-(7-chloro-1H-indol-3-yl)-3-trifluoromethyl-4,5-dihydropyrazol-1-yl]-benzenesulfonamide
-
0.01 mM inhibits LOX-5 by 94%
4-[[4-(2,4-dichlorophenyl)-5-methyl-1,3-thiazol-2-yl]amino]-2,6-dimethylphenol
-
lead compound, in vitro pharmacokinetic profile, shows no cytotoxicity, overview
4-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]phenol
-
-
4-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]imino]cyclohexa-2,5-dien-1-one
-
-
4-[[hydroxy(2-methyl-1-[3-[(morpholin-4-yl)oxy]phenyl]propyl)amino]methyl]phenol
-
-
5-methoxy-3-tridecylbenzene-1,2,4-triol
-
-
5-[[hydroxy(2-methyl-1-[3-[(morpholin-4-yl)oxy]phenyl]propyl)amino]methyl]benzene-1,2,3-triol
-
-
6-hydroxy-3,4-dimethoxy-5-undecylcyclohexa-2,4-dien-1-one
-
-
6-[(4-hydroxy-3,6-dioxocyclohexa-1,4-dien-1-yl)methyl]naphthalene-2-carboxylic acid
-
-
7,17(S)-dihydroxydocosahexaenoic acid
-
IC50: 0.007 mM
7-([3-fluoro-5-[(1R)-1-hydroxy-1-pyridin-2-ylpropyl]phenoxy]methyl)-4-furan-3-yl-2H-chromen-2-one
-
IC50: 175 nM
7-([3-fluoro-5-[(1R,3R,5S)-3-hydroxy-6,8-dioxabicyclo[3.2.1]oct-3-yl]phenoxy]methyl)-4-(4-fluorophenyl)-2H-chromen-2-one
-
-
7-([3-fluoro-5-[(1R,3R,5S)-3-hydroxy-6,8-dioxabicyclo[3.2.1]oct-3-yl]phenoxy]methyl)-4-furan-3-yl-2H-chromen-2-one
-
IC50: 200 nM
7-([3-fluoro-5-[(1R,3R,5S)-3-hydroxy-6,8-dioxabicyclo[3.2.1]oct-3-yl]phenoxy]methyl)-4-phenyl-2H-chromen-2-one
-
IC50: 300 nM
7-([3-fluoro-5-[(1S)-1-hydroxy-1-(1,3-thiazol-2-yl)propyl]phenoxy]methyl)-4-(4-fluorophenyl)-2H-chromen-2-one
-
IC50: 175 nM
7-([3-fluoro-5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]sulfanyl)-4-furan-3-yl-2H-chromen-2-one
-
IC50: 9 nM
7-([3-fluoro-5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]sulfanyl)-4-phenyl-2H-chromen-2-one
-
IC50: 26 nM
7-[[3-(1-ethyl-1-hydroxypropyl)-5-fluorophenoxy]methyl]-4-furan-3-yl-2H-chromen-2-one
-
IC50: 15 nM
AA-861
-
competitive 5-LO inhibitor
AA861
-
specific inhibition
ABT-761
-
-
arachidonate
-
substrate inhibition
benzyl 2-(3-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
benzyl 2-(4-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
beta-hydroxyacteoside
-
enzyme from polymorphonuclear leukocyte
biphenyl-2,4-diol
-
-
biphenyl-3-yl 3,5-dinitrobenzoate
-
-
biphenyl-4-yl 3,5-dinitrobenzoate
-
-
BRP-7
-
benzimidazole derivative BRP-7 inhibits leukotriene biosynthesis in vitro and in vivo by targeting 5-lipoxygenase-activating protein (FLAP). BRP-7 blocks 5-LOX co-localization with FLAP at the nuclear envelope in neutrophils. No complete inhibition up to 0.01 mM
-
BW755C
-
CAS: 66000-40-6; i.e. 3-amino-1-[3-(trifluoromethyl)phenyl]-2-pyrazoline, IC50: 0.013 mM
BWA-4C
-
-
-
BWA4C
caffeic acid
-
-
cannabidiol
-
-
capsaicin
-
enzyme from polymorphonuclear leukocyte
celecoxib
CGP28238
-
-
cholesterol
-
addition to a membrane preperation in vitro reduces 5-lipoxygenase activity by half. Cholesterol sulfate can inhibit 5-lipoxygenase in intact cells
CJ-13,610
-
-
CJ-13610
-
-
Cox-189
-
-
daidzein
-
noncompetitive
delphinidin 3-O-galactoside
-
from Vaccinium myrtillus berries, strong inhibitor, in a concentration-dependent manner
delphinidin 3-O-glucoside
-
from Vaccinium myrtillus berries, strong inhibitor, in a concentration-dependent manner
Diamide
-
in 5-LO/FLAP-transfected HeLa cells, treatment with the thiol-oxidizing agent diamide which promotes glutathionylation at surface Cys residues leads to a decreased leukotriene synthesis by wild-type 5-LO
diclofenac
-
-
eltenac
-
-
embelin
-
-
ER-34122
-
-
ethyl 1-benzyl-2-(4-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-((2,4-difluorophenylthio)methyl)-5-hydroxy-1-methyl-1H-indole-3-carboxylate
-
-
ethyl 2-((2,6-dichlorophenylthio)methyl)-5-hydroxy-1-methyl-1H-indole-3-carboxylate
-
-
ethyl 2-((2,6-dimethylphenylthio)methyl)-5-hydroxy-1-methyl-1H-indole-3-carboxylate
-
-
ethyl 2-((3,5-dimethylphenylthio)methyl)-5-hydroxy-1-methyl-1H-indole-3-carboxylate
-
-
ethyl 2-((3-chlorophenylthio)methyl)-5-hydroxy-1-methyl-1H-indole-3-carboxylate
-
-
ethyl 2-((4-fluorophenylthio)methyl)-5-hydroxy-1-methyl-1H-indole-3-carboxylate
-
-
ethyl 2-(2-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(2-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
-
-
ethyl 2-(3-bromobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(3-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(3-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
-
-
ethyl 2-(3-chlorobenzyl)-5-hydroxy-1H-pyrrolo[2,3-f]quinoline-3-carboxylate
-
-
ethyl 2-(3-chlorobenzyl)-5-hydroxy-6-phenyl-1H-indole-3-carboxylate
-
-
ethyl 2-(3-chlorobenzyl)-5-methoxy-1-methyl-1H-benzo[g]-indole-3-carboxylate
-
-
ethyl 2-(3-chlorobenzyl)-5-phenyl-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(3-chlorobenzyl)-7,8-dimethoxy-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(3-chlorophenyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(3-chlorophenyl)-5-hydroxy-1H-indole-3-carboxylate
-
-
ethyl 2-(3-fluorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(3-methoxybenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(4-bromobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(4-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(4-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
-
-
ethyl 2-(4-chlorophenyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(4-chlorophenyl)-5-hydroxy-1H-indole-3-carboxylate
-
-
ethyl 2-(4-fluorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(4-methoxybenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-(4-trifluoromethylbenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-[(3-chlorophenyl)-amino]-5-hydroxy-1H-indole-3-carboxylate
-
-
ethyl 2-[2-(3-chlorophenyl)ethyl]-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-[2-(3-chlorophenyl)ethyl]-5-hydroxy-1H-indole-3-carboxylate
-
-
ethyl 2-[2-(4-chlorophenyl)ethyl]-5-hydroxy-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 2-[2-(4-chlorophenyl)ethyl]-5-hydroxy-1H-indole-3-carboxylate
-
-
ethyl 2-[[4-chloro-6-(quinolin-6-ylamino)pyrimidin-2-yl]sulfanyl]octanoate
-
-
ethyl 5-benzoyloxy-2-(3-chlorobenzyl)-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 5-hydroxy-1-methyl-2-((2-(trifluoromethyl)phenylthio)methyl)-1H-indole-3-carboxylate
-
-
ethyl 5-hydroxy-1-methyl-2-((4-(trifluoromethoxy)phenylthio)methyl)-1H-indole-3-carboxylate
-
-
ethyl 5-hydroxy-1-methyl-2-((4-(trifluoromethyl)phenylthio)methyl)-1H-indole-3-carboxylate
-
-
ethyl 5-hydroxy-1-methyl-2-(phenylthiomethyl)-1H-indole-3-carboxylate
-
-
ethyl 5-hydroxy-2-((2-methoxyphenylthio)methyl)-1-methyl-1H-indole-3-carboxylate
-
-
ethyl 5-hydroxy-2-((4-methoxyphenylthio)methyl)-1-methyl-1H-indole-3-carboxylate
-
-
ethyl 5-hydroxy-2-(mesitylthiomethyl)-1-methyl-1H-indole-3-carboxylate
-
-
-
ethyl 5-hydroxy-2-phenylethyl-1H-indole-3-carboxylate
-
-
ethyl 5-hydroxy-2-phenylpropyl-1H-benzo[g]indole-3-carboxylate
-
-
ethyl 6-biphenyl-4-yl-(3-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
-
-
ethyl [2-[(2-[1-[4-(2-methylpropyl)phenyl]ethyl]-1H-benzimidazol-1-yl)methyl]phenoxy]acetate
-
a BRP-7 derivative
etoricoxib
-
-
Eugenol
-
non-competitive, reversible inhibitor, IC50: 0.026 mM
forsythiaside
-
enzyme from polymorphonuclear leukocyte
genistein
-
noncompetitive
gingerdione
-
enzyme from polymorphonuclear leukocyte
glutathione
helenalin
-
enzyme from polymorphonuclear leukocyte
hyperforin
-
-
idebenone
-
-
L-656,224
-
i.e. 7-chloro-2-[(4-methoxyphenyl)-methyl]-3-methyl-5-propyl-4-benzofuranol, IC50: 0.0008 mM
L-670,630
-
IC50: 0.0004 mM
L-689,065
-
IC50: 0.0003 mM
L-697,198
-
IC50: 0.00002 mM
-
L-702,590
-
-
-
L-702,701
-
IC50: 0.0015 mM
-
L-739,010
-
-
L-746,530
-
IC50: 27 nM
L705,302
-
IC50: 0.00002 mM
-
licofelone
meloxicam
-
-
methanol
-
complete inhibition at 50% v/v
methyl (4-[(5E)-5-(4-methoxybenzylidene)-4-oxo-4,5-dihydro-1,3-thiazol-2-yl]phenoxy)acetate
-
-
methyl 2-(allylamino)-1H-indole-3-carboxylate
-
-
methyl 2-(benzylamino)-1H-indole-3-carboxylate
-
-
methyl 2-(diallylamino)-1H-indole-3-carboxylate
-
-
methyl 2-[(2-chlorophenyl)amino]-1H-indole-3-carboxylate
-
-
methyl 2-[(3-bromophenyl)amino]-1H-indole-3-carboxylate
-
-
methyl 2-[(3-chlorophenyl)amino]-1H-indole-3-carboxylate
-
-
methyl 2-[(3-chlorophenyl)amino]-5-chloro-1H-indole-3-carboxylate
-
-
methyl 2-[(3-fluorophenyl)amino]-1H-indole-3-carboxylate
-
-
methyl 2-[(4-chlorophenyl)amino]-1H-indole-3-carboxylate
-
-
miogadial
-
potent inhibitor, IC50: 0.004 mM
miogatrial
-
potent inhibitor, IC50: 0.0075 mM
mithramycin
-
reduces endogenous 5-lipoxygenase in Mono Mac 6 cell, which blocks GC-boxes in the proximal part of the 5-lipoxygenase gene promoter
MK 886
-
i.e. CAS: 118414-82-7, inhibition of 5-lipoxygenase in prostate cancer cells blocks production of 5-hydroxyeicosatetraenoic acid and induces massive apoptosisin both hormone-responsive and hormone-nonresponsive prostate cancer cells
MK-886
MK886
ML-3000
-
i.e. licofelone, ML-3000 has no effect on 5-LOX product synthesis in whole-blood assay, inhibition of COX pathways does not increase the transformation of arachidonic acid by the 5-LOX pathway
myxochelin A
-
isolated from extracts of the predatory myxobacterium Pyxidicoccus fallax HKI 727, IC50 values for inhibition of proliferative cells K-562 and HeLa are 0.3052 mM and 0.0039 mM, respectively
-
myxochelin C
-
isolated from extracts of the predatory myxobacterium Pyxidicoccus fallax HKI 727, IC50 values for inhibition of proliferative cells K-562 and HeLa are 0.424 mM and 0.0535 mM, respectively
-
myxochelin D
-
isolated from extracts of the predatory myxobacterium Pyxidicoccus fallax HKI 727, IC50 values for inhibition of proliferative cells K-562 and HeLa are above 0.5 mM
-
N-(3,4-dimethoxyphenyl)-3,5-dinitrobenzamide
-
-
N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)-1,3-benzodioxole-5-carboxamide
-
-
N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)cyclopentanecarboxamide
-
-
N-(3-bromobenzyl)-3,5-dinitrobenzamide
-
-
N-(3-bromophenyl)-3,5-dinitrobenzamide
-
-
N-(3-chlorophenyl)-3,5-dinitrobenzamide
-
-
N-(3-phenoxycinnamyl)-acetohydroxamic acid
-
-
N-(4-chlorophenyl)-N-hydroxy-N'-(3-chlorophenyl)urea
-
IC50: 0.0001 mM
N-(4-methoxyphenyl)-3,5-dinitrobenzamide
-
-
N-(biphenyl-3-yl)-3,5-dinitrobenzamide
-
-
N-(furan-2-ylmethyl)-2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide
-
-
N-(naphthalene-1-yl)-3,5-dinitrobenzamide
-
-
N-([4-[(2E)-3-(2,4-dichlorophenyl)prop-2-enoyl]phenyl]carbamoyl)-4-methylbenzenesulfonamide
-
IC50: 0.00045 mM
N-3-tolyl-3,5-dinitrobenzamide
-
-
-
N-cyclopentyl-2-[7-(2-methoxyethoxy)-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl]propanamide
-
-
N-hydroxy-N-[(2E)-3-(3-phenoxyphenyl)prop-2-en-1-yl]acetamide
-
-
N-phenyl-3,5-dinitrobenzamide
-
-
-
N-tert-butyl-2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide
-
-
naphthalen-1-yl 3,5-dinitrobenzoate
-
JMC-4, identified from virtual inhibitor screening
-
naphthalene-1-yl 3-nitrobenzoate
-
-
nimesulide
-
-
nordihydroguaiaretic acid
parecoxib
-
-
phenyl 3,5-dinitrobenzoate
-
-
polygodial
-
strong inhibitory activity, IC50: 0.0086 mM
Rev-5901
-
competitive 5-LO inhibitor
rofecoxib
RWJ-63556
-
-
S-2474
-
-
SC-560
-
-
SC-756
-
-
shogaol
-
enzyme from polymorphonuclear leukocyte
sulindac sulfide
suspensaside
-
enzyme from polymorphonuclear leukocyte
tepoxalin
-
-
U73122
-
-
valdecoxib
-
-
verbascoside
-
enzyme from polymorphonuclear leukocyte
YS121
-
-
ZD 2138
ZD-2138
-
-
Zileutin
-
-
zileuton
ZM 230,486
-
IC50: 0.00009 mM
ZM230487
-
-
[1-(2-[[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]ethyl)-1H-1,2,3-triazol-4-yl]methyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
-
-
[1-(2-[[(2E)-3-phenylprop-2-enoyl]oxy]ethyl)-1H-1,2,3-triazol-4-yl]methyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
-
-
[1-(2-[[(2E)-3-phenylprop-2-enoyl]oxy]ethyl)-1H-1,2,3-triazol-4-yl]methyl (2E)-3-phenylprop-2-enoate
-
shows less inhibitory activity than the corresponding clusters bearing the caffeic acid moiety
[1-(3-[4-([[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]methyl)-1H-1,2,3-triazol-1-yl]-2-[(3-[4-([[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]methyl)-1H-1,2,3-triazol-1-yl]-2,2-bis[[4-([[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]methyl)-1H-1,2,3-triazol-1-yl]methyl]propoxy)methyl]-2-[[4-([[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]methyl)-1H-1,2,3-triazol-1-yl]methyl]propyl)-1H-1,2,3-triazol-4-yl]methyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
-
incorporation of additional caffeoyl units in hexamer results in less potent inhibition
[1-(3-[4-([[(2E)-3-phenylprop-2-enoyl]oxy]methyl)-1H-1,2,3-triazol-1-yl]-2-[(3-[4-([[(2E)-3-phenylprop-2-enoyl]oxy]methyl)-1H-1,2,3-triazol-1-yl]-2,2-bis[[4-([[(2E)-3-phenylprop-2-enoyl]oxy]methyl)-1H-1,2,3-triazol-1-yl]methyl]propoxy)methyl]-2-[[4-([[(2E)-3-phenylprop-2-enoyl]oxy]methyl)-1H-1,2,3-triazol-1-yl]methyl]propyl)-1H-1,2,3-triazol-4-yl]methyl (2E)-3-phenylprop-2-enoate
-
shows less inhibitory activity than the corresponding clusters bearing the caffeic acid moiety
[2-[(2-methyl-1H-benzimidazol-1-yl)methyl]phenoxy]acetyl chloride
-
a BRP-7 derivative
[3-(1-[hydroxy[(3,4,5-trihydroxyphenyl)methyl]amino]ethyl)phenyl](morpholin-4-yl)methanone
-
-
[3-(1-[hydroxy[(4-hydroxyphenyl)methyl]amino]ethyl)phenyl](morpholin-4-yl)methanone
-
-
[3-(bromocarbonyl)phenyl](morpholin-4-yl)acetic acid
-
-
additional information
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
1,25(OH)2D3
-
gives a strong (100fold) upregulation of 5-lipoxygenase protein in differentiating Mono Mac 6 cells
5-lipoxygenase activating protein
-
5-lipoxygenase activating protein is crucial for conversion of endogenous substrate by 5LO 5-lipoxygenase activating protein also stimulates the utilization of exogenous arachidonic acid, and greatly (190fold) stimulates utilization of (5Z,8Z,10E,12S,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoic acid
-
5-lipoxygenase-activating protein
-
functional 5-LOX requires binding to 5-lipoxygenase-activating protein which helps 5-LOX binding to arachidonic acid at the nuclear membrane and enhances the efficiency of leukotriene synthesis
-
5-LO activating protein
-
i.e. FLAP, Ca2+ induces the translocation of 5-LO from a soluble compartment to nuclear structures, where 5-LO co-localizes with 5-LO activating protein
-
5-LOX activating protein
-
-
-
adenosine
-
58% of the activation with ATP
ADP
-
74% of the activation with ATP
ADP-beta-S
-
82% of the activation with ATP
AMP
-
68% of the activation with ATP
AMP-4-nitrophenylphosphate
-
77% of the activation with ATP
ATP-alphaS
-
118% of the activation with ATP
ATP-gammaS
-
80% of the activation with ATP
CLP
-
can upregulate and modulate the 5-lipoxygenase pathway in vitro
-
coactosin-like protein
-
FLAP
-
Nicotine
-
treatment with 0.01 mM nicotine activates 5-lipoxygenase gastric cancer cell lines from 36-72 h
phosphatidylcholine
phosphocholine
-
phosphocholine in combination with Ca2+ markedly stimulate the formation of leukotrienes by wild-type 5-LO and mutant C159S/C300S/C416S/C418S, whereas their effect on the 5-LO W13A/W75A/W102A mutant is small
protein factors from human leukocyte
-
transforming growth factor beta
-
gives a strong (100fold) upregulation of 5-lipoxygenase protein in differentiating Mono Mac 6 cells
-
additional information
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.014 - 0.019
(5S,6E,8Z,11Z,14Z)-5-hydroperoxyicosa-6,8,11,14-tetraenoate
0.0093 - 0.01144
7,7-d2-arachidonate
-
0.0051 - 0.053
arachidonate
0.012
arachidonic acid
-
-
additional information
additional information
-
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.001 - 0.01
7,7-d2-arachidonate
-
0.004 - 0.06
arachidonate
kcat/KM VALUE [1/mMs-1]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.108 - 0.87
7,7-d2-arachidonate
-
0.14 - 2.69
arachidonate
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.00071
(2,4-dihydroxyphenyl)[3-(1-[hydroxy[(3,4,5-trihydroxyphenyl)methyl]amino]ethyl)phenyl]methanone
-
pH and temperature not specified in the publication
0.0009
(2,4-dihydroxyphenyl)[3-(1-[hydroxy[(4-hydroxyphenyl)methyl]amino]ethyl)phenyl]methanone
-
pH and temperature not specified in the publication
0.016
2-(3-acetylphenyl)propanoic acid
-
pH and temperature not specified in the publication
0.00136
2-(3-benzoylphenyl)propanoic acid
-
pH and temperature not specified in the publication
-
0.00267
2-(3-phenoxyphenyl)propanoic acid
-
pH and temperature not specified in the publication
0.0455
2-methyl-3-[(morpholine-4-carbonyl)amino]-3-oxopropanoic acid
-
pH and temperature not specified in the publication
0.00734
2-[3-(2-methylpropanoyl)phenyl]propanoic acid
-
pH and temperature not specified in the publication
0.00734
2-[3-(morpholine-4-carbonyl)phenyl]propanoic acid
-
pH and temperature not specified in the publication
0.00042
2-[3-[(4-hydroxyphenyl)carbamoyl]phenyl]propanoic acid
-
pH and temperature not specified in the publication
0.0057
2-[3-[hydroxy(phenyl)amino]phenyl]propanoic acid
-
pH and temperature not specified in the publication
0.00013
2-[4'-[(morpholin-4-yl)sulfanyl][1,1'-biphenyl]-3-yl]propanoic acid
-
pH and temperature not specified in the publication
0.0112
2-[4-(morpholine-4-carbonyl)phenyl]propanoic acid
-
pH and temperature not specified in the publication
0.17
3-(1-carboxyethyl)benzoic acid
-
pH and temperature not specified in the publication
0.00515
4-[(hydroxy[1-[3'-(morpholin-4-yl)[1,1'-biphenyl]-3-yl]ethyl]amino)methyl]phenol
-
pH and temperature not specified in the publication
0.00011
4-[[hydroxy(2-methyl-1-[3-[(morpholin-4-yl)oxy]phenyl]propyl)amino]methyl]phenol
-
pH and temperature not specified in the publication
0.00032
5-[[hydroxy(2-methyl-1-[3-[(morpholin-4-yl)oxy]phenyl]propyl)amino]methyl]benzene-1,2,3-triol
-
pH and temperature not specified in the publication
0.0398
arachidonate
-
pH and temperature not specified in the publication
0.00059
[3-(1-[hydroxy[(3,4,5-trihydroxyphenyl)methyl]amino]ethyl)phenyl](morpholin-4-yl)methanone
-
pH and temperature not specified in the publication
0.00018
[3-(1-[hydroxy[(4-hydroxyphenyl)methyl]amino]ethyl)phenyl](morpholin-4-yl)methanone
-
pH and temperature not specified in the publication
0.0398
[3-(bromocarbonyl)phenyl](morpholin-4-yl)acetic acid
-
pH and temperature not specified in the publication
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.00066 - 0.00246
(2E,2'E)-(1,1'-(2,2-bis((4-(((E)-3-(3,4-dihydroxyphenyl)acryloyloxy)methyl)-1H-1,2,3-triazol-1-yl)methyl)propane-1,3-diyl)bis(1H-1,2,3-triazole-4,1-diyl))bis(methylene) bis(3-(3,4-dihydroxyphenyl)acrylate)
0.00079 - 0.00237
(2E,2'E)-(1,1'-(2-((4-(((E)-3-(3,4-dihydroxyphenyl)acryloyloxy)methyl)-1H-1,2,3-triazol-1-yl)methyl)-2-(hydroxymethyl)propane-1,3-diyl)bis(1H-1,2,3-triazole-4,1-diyl))bis(methylene) bis(3-(3,4-dihydroxyphenyl)acrylate)
0.03
(2E,5E)-5-[(2E)-3-(furan-2-yl)prop-2-en-1-ylidene]-3-phenyl-2-(phenylimino)-1,3-thiazolidin-4-one
Homo sapiens;
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication; a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.00013 - 0.00038
(5E)-2-(3-acetylphenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
0.00012 - 0.00024
(5E)-2-(3-fluorophenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
0.00011 - 0.00055
(5E)-2-(4-acetylphenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
0.00063 - 0.00193
(5E)-2-(4-aminophenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
0.00011 - 0.0004
(5E)-2-(4-chlorophenyl)-5-(4-hydroxybenzylidene)-1,3-thiazol-4(5H)-one
0.00009 - 0.00028
(5E)-2-(4-chlorophenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
0.00065 - 0.00169
(5E)-2-(4-hydroxyphenyl)-5-(4-methoxybenzylidene)-1,3-thiazol-4(5H)-one
0.0004 - 0.00245
(5E)-2-(4-methylphenyl)-5-(3,4,5-trimethoxybenzylidene)-1,3-thiazol-4(5H)-one
0.00098 - 0.00202
(5E)-5-(2,4-dimethoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
0.0008 - 0.0013
(5E)-5-(2-hydroxy-3-methoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
0.00048 - 0.00054
(5E)-5-(2-hydroxy-3-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
0.00013 - 0.00035
(5E)-5-(3,5-dimethoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
0.0027 - 0.01
(5E)-5-(3-chloro-4-hydroxy-5-methoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
0.003 - 0.0095
(5E)-5-(3-chloro-4-hydroxy-5-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
0.00125 - 0.0029
(5E)-5-(3-chloro-5-ethoxy-4-hydroxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
0.0003 - 0.00058
(5E)-5-(3-chlorobenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
0.003 - 0.0044
(5E)-5-(4-hydroxy-3-methoxy-5-nitrobenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
0.00032 - 0.004
(5E)-5-(4-methoxybenzylidene)-2-(4-methoxyphenyl)-1,3-thiazol-4(5H)-one
0.0003 - 0.00066
(5E)-5-(4-methoxybenzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
0.00015 - 0.002
(5E)-5-(4-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
0.0003 - 0.00091
(5E)-5-(4-tert-butylbenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
0.00019 - 0.00211
(5E)-5-(4-[(methylperoxy)acetyl]benzylidene)-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
0.0003 - 0.00065
(5E)-5-(5-chloro-2-hydroxy-3-methoxybenzylidene)-2-phenyl-1,3-thiazol-4(5H)-one
0.0003 - 0.004
(5E)-5-(anthracen-9-ylmethylidene)-2-phenyl-1,3-thiazol-4(5H)-one
0.00035 - 0.00073
(5E)-5-benzylidene-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
0.02 - 0.03
(5E)-5-[4-(dimethylamino)benzylidene]-2-(piperidin-1-yl)-1,3-thiazol-4(5H)-one
0.012 - 0.014
(5Z)-2-(cyclohexylamino)-5-(4-propoxybenzylidene)-1,3-thiazol-4(5H)-one
0.03
(5Z)-5-(4-methoxybenzylidene)-2-(pyrrolidin-1-yl)-1,3-thiazol-4(5H)-one
Homo sapiens;
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication; a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.03
(5Z)-5-(4-methylbenzylidene)-2-(naphthalen-2-ylamino)-1,3-thiazol-4(5H)-one
Homo sapiens;
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication; a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.03
(5Z)-5-benzylidene-2-(phenylamino)-1,3-thiazol-4(5H)-one
Homo sapiens;
-
a cell-based test system using isolated human polymorphonuclear leukocytes is applied, pH and temperature not specified in the publication; a cell-free assay utilizing the 100000g supernatant (S100) of human polymorphonuclear leukocytes (PMNL) homogenates is applied, pH and temperature not specified in the publication
0.005
([4-chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl]sulfanyl)(naphthalen-1-yl)acetic acid
Homo sapiens;
-
in intact polymorphonuclear leukocytes
0.0006 - 0.007
1-(2,4-difluorophenyl)-3-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)urea
0.0068 - 0.01
1-(2,4-dihydroxyphenyl)-2-(naphthalen-2-yl)ethanone
0.0013
1-(3-[5-(hydroxyureido)methyl-2-methoxyphenoxy]propyl)-3-[4-(trifluoromethoxy)phenyl]urea
Homo sapiens;
-
pH 7.4, 37°C
0.003 - 0.01
1-benzyl-3-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)urea
0.005
1-O-dodecyl 2,3-O-isopropylidene-5,6-dideoxy-5-N-[4-(2-hydroxy-2-oxoethyl) phenylaminocarbonyl] amino-beta-L-gulofuranoside sodium salt
Homo sapiens;
-
competitive inhibitior, IC50: 0.0035 mM with recombinant enzyme, IC50: 0.005 mM with native enzyme
0.001 - 0.004
1-[3-(methylsulfanyl)phenyl]-3-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)urea
0.017
10,17(S)-dihydroxydocosahexaenoic acid
Homo sapiens;
-
IC50: 0.017 mM
0.0048
15-hydroperoxy-6,8,11,13-eicosatetraenoic acid
Homo sapiens;
-
IC50: 0.0048 mM
0.05
2,3-dichlorophenyl 3,5-dinitrobenzoate
Homo sapiens;
-
pH 7.4, 37°C
0.00026
2,5-dimethoxy-3-tridecylbenzene-1,4-diol
Homo sapiens;
-
pH 7.4, 37°C, cell-free enzyme extract
0.0015
2-(2,2-dimethyl-6-(4-nitrophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)acetic acid
Homo sapiens;
-
-
0.00031
2-(2,2-dimethyl-7-phenyl-6-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrrolizin-5-yl)acetic acid
Homo sapiens;
-
-
0.004 - 0.01
2-(2-methoxyphenyl)-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)acetamide
0.0007 - 0.0015
2-(4-(biphenyl-4-ylamino)-6-chloropyrimidine-2-ylthio)octanoic acid
0.001 - 0.002
2-(4-(biphenyl-4-ylmethylamino)-6-chloropyrimidin-2-ylthio)octanoic acid
0.0004 - 0.0015
2-(4-chloro-6-(4'-cyanobiphenyl-4-ylamino)pyrimidin-2-ylthio)octanoic acid
0.0005 - 0.002
2-(4-chloro-6-(5-methoxy-2-methylbiphenyl-4-ylamino)pyrimidin-2-ylthio)octanoic acid
0.00023 - 0.0004
2-(4-methylphenyl)-5-(2-phenylethenylidene)-1,3-thiazol-4(5H)-one
0.0008 - 0.001
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-(5-methyl-1,3-thiazol-2-yl)propanamide
0.0008 - 0.001
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-1,3-thiazol-2-ylpropanamide
0.0009 - 0.006
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-pyridin-2-ylpropanamide
0.003 - 0.008
2-(5,8-dimethyl-7-propoxy-1,2,3,4-tetrahydronaphthalen-2-yl)-N-thiophen-3-ylpropanamide
0.00023
2-(6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)-N-(methylsulfonyl)acetamide
Homo sapiens;
-
-
0.00025
2-(6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)-N-(phenylsulfonyl)acetamide
Homo sapiens;
-
-
0.00026
2-(6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)-N-tosylacetamide
Homo sapiens;
-
-
0.0016
2-(6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)acetic acid
Homo sapiens;
-
-
0.00018
2-(6-(4-tert-butylphenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl)acetic acid
Homo sapiens;
-
-
0.008 - 0.01
2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)-N-(thiophen-2-ylmethyl)propanamide
0.0008 - 0.005
2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)-N-pyridin-2-ylpropanamide
0.0008 - 0.01
2-(dibenzo[b,d]furan-3-yl)-5-hydroxycyclohexa-2,5-diene-1,4-dione
0.0041 - 0.0065
2-([4-chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl]sulfanyl)octanoic acid
0.01
2-benzyl-5-hydroxycyclohexa-2,5-diene-1,4-dione
Homo sapiens;
-
value above, pH not specified in the publication, 37°C, cell-based test system; value above, pH not specified in the publication, 37°C, cell-free based test system
0.0014 - 0.003
2-hexyl-5-hydroxycyclohexa-2,5-diene-1,4-dione
0.0046 - 0.01
2-hydroxy-5-(3-nitrophenyl)cyclohexa-2,5-diene-1,4-dione
0.00078 - 0.0023
2-hydroxy-5-(naphthalen-2-ylmethyl)cyclohexa-2,5-diene-1,4-dione
0.01
2-hydroxy-5-methoxy-3-(naphthalen-2-ylmethyl)cyclohexa-2,5-diene-1,4-dione
Homo sapiens;
-
value above, pH not specified in the publication, 37°C, cell-based test system; value above, pH not specified in the publication, 37°C, cell-free based test system
0.00028 - 0.0067
2-methoxy-5-(naphthalen-2-yloxy)cyclohexa-2,5-diene-1,4-dione
0.0015 - 0.003
2-[(4-[[3,5-bis(2,2,2-trifluoroethoxy)phenyl]amino]-6-chloropyrimidin-2-yl)sulfanyl]octanoic acid
0.006
2-[4'-(iso-propylphenyl)-amino]-5,6-dimethyl-1,4-benzoquinone
Homo sapiens;
-
potent inhibitor, IC50: 0.006 mM
0.00068
2-[4-([[(2E)-3-phenylprop-2-enoyl]oxy]methyl)-1H-1,2,3-triazol-1-yl]ethyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
Homo sapiens;
-
; per number of caffeic acid moieties
0.00018
2-[6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl]acetic acid
Homo sapiens;
-
-
0.001 - 0.01
2-[7-[2-(dimethylamino)ethoxy]-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl]-N-1,3-thiazol-2-ylpropanamide
0.01
3'-nitrobiphenyl-2,4-diol
Homo sapiens;
-
value above,pH not specified in the publication, 37°C, cell-based test system; value above, pH not specified in the publication, 37°C, cell-free based test system
0.0009 - 0.01
3,4,5-trimethoxy-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)benzamide
0.00031
3,4,6-trimethoxy-5-undecylcyclohexa-2,4-dien-1-one
Homo sapiens;
-
pH 7.4, 37°C, cell-free enzyme extract
0.05
3-((naphthalene-1-yloxy)carbonyl)benzoic acid
Homo sapiens;
-
pH 7.4, 37°C
0.00146
3-(1,10-dihydroxydecyl)-2,5-dimethoxycyclohexa-2,5-diene-1,4-dione
Homo sapiens;
-
pH 7.4, 37°C, cell-free enzyme extract
0.00049
3-(1-acetoxy-10-hydroxydecyl)-2,5-dimethoxycyclohexa-2,5-diene-1,4-dione
Homo sapiens;
-
pH 7.4, 37°C, cell-free enzyme extract
0.00175
3-(10-hydroxydecyl)-2,5-dimethoxycyclohexa-2,5-diene-1,4-dione
Homo sapiens;
-
pH 7.4, 37°C, cell-free enzyme extract
0.00108
3-(10-hydroxydecyl)-4,5-dimethoxycyclohexa-3,5-diene-1,2-dione
Homo sapiens;
-
pH 7.4, 37°C, cell-free enzyme extract
0.00151
3-(11-hydroxyundecyl)-2,5-dimethoxycyclohexa-2,5-diene-1,4-dione
Homo sapiens;
-
pH 7.4, 37°C, cell-free enzyme extract
0.00196
3-(11-hydroxyundecyl)-4,5-dimethoxycyclohexa-3,5-diene-1,2-dione
Homo sapiens;
-
pH 7.4, 37°C, cell-free enzyme extract
0.00184
3-(8-hydroxyoctyl)-2,5-dimethoxycyclohexa-2,5-diene-1,4-dione
Homo sapiens;
-
pH 7.4, 37°C, cell-free enzyme extract
0.00022
3-(8-hydroxyoctyl)-4,5-dimethoxycyclohexa-3,5-diene-1,2-dione
Homo sapiens;
-
pH 7.4, 37°C, cell-free enzyme extract
0.05
3-(benzyloxycarbonyl)benzoic acid
Homo sapiens;
-
pH 7.4, 37°C
0.01
3-(cyclohexylmethyl)-2,5-dihydroxycyclohexa-2,5-diene-1,4-dione
Homo sapiens;
-
value above, pH not specified in the publication, 37°C, cell-based test system; value above, pH not specified in the publication, 37°C, cell-free based test system
0.00058 - 0.011
3-(decahydronaphthalen-2-ylmethyl)-2,5-dihydroxycyclohexa-2,5-diene-1,4-dione
0.05
3-(naphhthalen-1-ylcarbmoyl)benzoic acid
Homo sapiens;
-
pH 7.4, 37°C
0.05
3-(phenylcarbamoyl)benzoic acid
Homo sapiens;
-
pH 7.4, 37°C
0.01
3-benzyl-2-hydroxy-5-methoxycyclohexa-2,5-diene-1,4-dione
Homo sapiens;
-
value above, pH not specified in the publication, 37°C, cell-based test system; value above, pH not specified in the publication, 37°C, cell-free based test system
0.00024
3-dodecyl-4,5-dimethoxybenzene-1,2-diol
Homo sapiens;
-
pH 7.4, 37°C, cell-free enzyme extract
0.00013
3-dodecyl-4,5-dimethoxycyclohexa-3,5-diene-1,2-dione
Homo sapiens;
-
pH 7.4, 37°C, cell-free enzyme extract
0.0065
3-propylphenyl 3,5-dinitrobenzoate
Homo sapiens;
-
pH 7.4, 37°C
0.0005
3-tolyl 3,5-dinitrobenzoate
Homo sapiens;
-
pH 7.4, 37°C
0.00006
3-tridecyl-4,5-dimethoxybenzene-1,2-diol
Homo sapiens;
-
pH 7.4, 37°C, cell-free enzyme extract
0.0001
3-undecyl-4,5-dimethoxybenzene-1,2-diol
Homo sapiens;
-
pH 7.4, 37°C, cell-free enzyme extract
0.00008
4,5-dimethoxy-3-tridecylcyclohexa-3,5-diene-1,2-dione
Homo sapiens;
-
pH 7.4, 37°C, cell-free enzyme extract
0.00009
4,5-dimethoxy-3-undecylcyclohexa-3,5-diene-1,2-dione
Homo sapiens;
-
pH 7.4, 37°C, cell-free enzyme extract
0.01
4-(1-benzothiophen-3-yl)benzene-1,3-diol
Homo sapiens;
-
value above, pH not specified in the publication, 37°C, cell-based test system; value above, pH not specified in the publication, 37°C, cell-free based test system
0.00004
4-(4-(4-chlorophenyl)thiazol-2-ylimino)cyclohexa-2,5-dienone
Homo sapiens;
-
pH 7.4, 37°C, recombinant enzyme
-
0.00018
4-(4-chlorophenyl)-7-([3-fluoro-5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]sulfanyl)-2H-chromen-2-one
Homo sapiens;
-
IC50: 180 nM
0.000055
4-(4-fluorophenyl)-7-([3-fluoro-5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenoxy]methyl)-2H-chromen-2-one
Homo sapiens;
-
IC50: 55 nM
0.000027
4-(4-fluorophenyl)-7-([3-fluoro-5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]sulfanyl)-2H-chromen-2-one
Homo sapiens;
-
IC50: 27 nM
0.0063 - 0.01
4-(dibenzo[b,d]furan-3-yl)benzene-1,3-diol
0.0023 - 0.0074
4-(naphthalen-2-ylmethyl)benzene-1,3-diol
0.0021 - 0.0032
4-(thianthren-2-yl)benzene-1,3-diol
0.009 - 0.01
4-benzylbenzene-1,3-diol
0.00042
4-chloro-N-([4-[(2E)-3-(2,4-dichlorophenyl)prop-2-enoyl]phenyl]carbamoyl)benzenesulfonamide
Homo sapiens;
-
IC50: 0.00042 mM
0.00083
4-chloro-N-([4-[(2E)-3-phenylprop-2-enoyl]phenyl]carbamoyl)benzenesulfonamide
Homo sapiens;
-
IC50: 0.00083 mM
0.0028 - 0.0046
4-hexylbenzene-1,3-diol
0.006 - 0.01
4-methoxy-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)benzamide
0.01
4-methyl-N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)-1,2,3-thiadiazole-5-carboxamide
Homo sapiens;
-
37°C, intact polymorphonuclear leukocytes; above, 37°C, partially purified enzyme
0.00045
4-methyl-N-([4-[(2E)-3-(2,3,4-trimethylphenyl)prop-2 enoyl]phenyl]carbamoyl)benzenesulfonamide
Homo sapiens;
-
IC50: 0.00045 mM
0.00089
4-methyl-N-([4-[(2E)-3-phenylprop-2-enoyl]phenyl]carbamoyl)benzenesulfonamide
Homo sapiens;
-
IC50: 0.00089 mM
0.00003
4-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]phenol
Homo sapiens;
-
pH 7.4, 37°C, recombinant enzyme
0.00029
5-methoxy-3-tridecylbenzene-1,2,4-triol
Homo sapiens;
-
pH 7.4, 37°C, cell-free enzyme extract
0.00092
6-hydroxy-3,4-dimethoxy-5-undecylcyclohexa-2,4-dien-1-one
Homo sapiens;
-
pH 7.4, 37°C, cell-free enzyme extract
0.009 - 0.01
6-[(4-hydroxy-3,6-dioxocyclohexa-1,4-dien-1-yl)methyl]naphthalene-2-carboxylic acid
0.007
7,17(S)-dihydroxydocosahexaenoic acid
Homo sapiens;
-
IC50: 0.007 mM
0.000175
7-([3-fluoro-5-[(1R)-1-hydroxy-1-pyridin-2-ylpropyl]phenoxy]methyl)-4-furan-3-yl-2H-chromen-2-one
Homo sapiens;
-
IC50: 175 nM
0.0002
7-([3-fluoro-5-[(1R,3R,5S)-3-hydroxy-6,8-dioxabicyclo[3.2.1]oct-3-yl]phenoxy]methyl)-4-furan-3-yl-2H-chromen-2-one
Homo sapiens;
-
IC50: 200 nM
0.0003
7-([3-fluoro-5-[(1R,3R,5S)-3-hydroxy-6,8-dioxabicyclo[3.2.1]oct-3-yl]phenoxy]methyl)-4-phenyl-2H-chromen-2-one
Homo sapiens;
-
IC50: 300 nM
0.000175
7-([3-fluoro-5-[(1S)-1-hydroxy-1-(1,3-thiazol-2-yl)propyl]phenoxy]methyl)-4-(4-fluorophenyl)-2H-chromen-2-one
Homo sapiens;
-
IC50: 175 nM
0.000009
7-([3-fluoro-5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]sulfanyl)-4-furan-3-yl-2H-chromen-2-one
Homo sapiens;
-
IC50: 9 nM
0.000026
7-([3-fluoro-5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]sulfanyl)-4-phenyl-2H-chromen-2-one
Homo sapiens;
-
IC50: 26 nM
0.000015
7-[[3-(1-ethyl-1-hydroxypropyl)-5-fluorophenoxy]methyl]-4-furan-3-yl-2H-chromen-2-one
Homo sapiens;
-
IC50: 15 nM
0.00013 - 0.00035
benzyl 2-(3-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.00017 - 0.00048
benzyl 2-(4-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.0028 - 0.0042
biphenyl-2,4-diol
0.038
biphenyl-3-yl 3,5-dinitrobenzoate
Homo sapiens;
-
pH 7.4, 37°C
0.05
biphenyl-4-yl 3,5-dinitrobenzoate
Homo sapiens;
-
pH 7.4, 37°C
0.0048
BRP-7
Homo sapiens;
-
pH 7.4, 37°C
-
0.013
BW755C
Homo sapiens;
-
i.e. 3-amino-1-[3-(trifluoromethyl)phenyl]-2-pyrazoline, IC50: 0.013 mM
0.025
caffeic acid
Homo sapiens;
-
-
0.0195
celecoxib
Homo sapiens;
-
37°C, whole blood assay
0.00115 - 0.00155
CJ-13610
Homo sapiens;
-
pH 7.5, 37°C, dependent on assay method via fluorescence or UV measurement, kinetics, overview
0.157
daidzein
Homo sapiens;
-
pH 7.4, 27°C
0.0069
delphinidin 3-O-galactoside
Homo sapiens;
-
-
0.00215
delphinidin 3-O-glucoside
Homo sapiens;
-
-
0.00065 - 0.0018
ethyl 1-benzyl-2-(4-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.0032
ethyl 2-((2,4-difluorophenylthio)methyl)-5-hydroxy-1-methyl-1H-indole-3-carboxylate
Homo sapiens;
-
pH 7.4, 37°C, cell-free enzyme extract
0.0008
ethyl 2-((2,6-dichlorophenylthio)methyl)-5-hydroxy-1-methyl-1H-indole-3-carboxylate
Homo sapiens;
-
pH 7.4, 37°C, cell-free enzyme extract
0.0008
ethyl 2-((2,6-dimethylphenylthio)methyl)-5-hydroxy-1-methyl-1H-indole-3-carboxylate
Homo sapiens;
-
pH 7.4, 37°C, cell-free enzyme extract
0.0018
ethyl 2-((3,5-dimethylphenylthio)methyl)-5-hydroxy-1-methyl-1H-indole-3-carboxylate
Homo sapiens;
-
pH 7.4, 37°C, cell-free enzyme extract
0.0038
ethyl 2-((3-chlorophenylthio)methyl)-5-hydroxy-1-methyl-1H-indole-3-carboxylate
Homo sapiens;
-
pH 7.4, 37°C, cell-free enzyme extract
0.005
ethyl 2-((4-fluorophenylthio)methyl)-5-hydroxy-1-methyl-1H-indole-3-carboxylate
Homo sapiens;
-
pH 7.4, 37°C, cell-free enzyme extract
0.000097 - 0.0012
ethyl 2-(2-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.0016 - 0.0017
ethyl 2-(2-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
0.00015 - 0.00045
ethyl 2-(3-bromobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.000086 - 0.00023
ethyl 2-(3-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.0017 - 0.002
ethyl 2-(3-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
0.00058 - 0.0043
ethyl 2-(3-chlorobenzyl)-5-hydroxy-1H-pyrrolo[2,3-f]quinoline-3-carboxylate
0.0012 - 0.0057
ethyl 2-(3-chlorobenzyl)-5-hydroxy-6-phenyl-1H-indole-3-carboxylate
0.01 - 0.03
ethyl 2-(3-chlorobenzyl)-5-methoxy-1-methyl-1H-benzo[g]-indole-3-carboxylate
0.03
ethyl 2-(3-chlorobenzyl)-5-phenyl-1H-benzo[g]indole-3-carboxylate
Homo sapiens;
-
5-lipoxygenase inhibited in neutrophils; recombinant 5-lipoxygenase
0.007 - 0.01
ethyl 2-(3-chlorobenzyl)-7,8-dimethoxy-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.000045 - 0.00052
ethyl 2-(3-chlorophenyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.0033 - 0.0048
ethyl 2-(3-chlorophenyl)-5-hydroxy-1H-indole-3-carboxylate
0.00014 - 0.00034
ethyl 2-(3-fluorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.00013 - 0.00052
ethyl 2-(3-methoxybenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.000095 - 0.0006
ethyl 2-(4-bromobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.000084 - 0.0012
ethyl 2-(4-chlorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.0007 - 0.0012
ethyl 2-(4-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
0.000067 - 0.00032
ethyl 2-(4-chlorophenyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.002 - 0.0021
ethyl 2-(4-chlorophenyl)-5-hydroxy-1H-indole-3-carboxylate
0.000096 - 0.0005
ethyl 2-(4-fluorobenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.00015 - 0.00065
ethyl 2-(4-methoxybenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.00025 - 0.0017
ethyl 2-(4-trifluoromethylbenzyl)-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.0003 - 0.0024
ethyl 2-[(3-chlorophenyl)-amino]-5-hydroxy-1H-indole-3-carboxylate
0.000031 - 0.00049
ethyl 2-[2-(3-chlorophenyl)ethyl]-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.0017 - 0.0028
ethyl 2-[2-(3-chlorophenyl)ethyl]-5-hydroxy-1H-indole-3-carboxylate
0.000049 - 0.0028
ethyl 2-[2-(4-chlorophenyl)ethyl]-5-hydroxy-1H-benzo[g]indole-3-carboxylate
0.0007 - 0.0039
ethyl 2-[2-(4-chlorophenyl)ethyl]-5-hydroxy-1H-indole-3-carboxylate
0.0006 - 0.019
ethyl 2-[[4-chloro-6-(quinolin-6-ylamino)pyrimidin-2-yl]sulfanyl]octanoate
0.0034 - 0.01
ethyl 5-benzoyloxy-2-(3-chlorobenzyl)-1H-benzo[g]indole-3-carboxylate
0.0008
ethyl 5-hydroxy-1-methyl-2-((2-(trifluoromethyl)phenylthio)methyl)-1H-indole-3-carboxylate
Homo sapiens;
-
pH 7.4, 37°C, cell-free enzyme extract
0.0009
ethyl 5-hydroxy-1-methyl-2-((4-(trifluoromethoxy)phenylthio)methyl)-1H-indole-3-carboxylate
Homo sapiens;
-
pH 7.4, 37°C, cell-free enzyme extract
0.0042
ethyl 5-hydroxy-1-methyl-2-((4-(trifluoromethyl)phenylthio)methyl)-1H-indole-3-carboxylate
Homo sapiens;
-
pH 7.4, 37°C, cell-free enzyme extract
0.0057
ethyl 5-hydroxy-1-methyl-2-(phenylthiomethyl)-1H-indole-3-carboxylate
Homo sapiens;
-
pH 7.4, 37°C, cell-free enzyme extract
0.0029
ethyl 5-hydroxy-2-((2-methoxyphenylthio)methyl)-1-methyl-1H-indole-3-carboxylate
Homo sapiens;
-
pH 7.4, 37°C, cell-free enzyme extract
0.0023
ethyl 5-hydroxy-2-((4-methoxyphenylthio)methyl)-1-methyl-1H-indole-3-carboxylate
Homo sapiens;
-
pH 7.4, 37°C, cell-free enzyme extract
0.0007
ethyl 5-hydroxy-2-(mesitylthiomethyl)-1-methyl-1H-indole-3-carboxylate
Homo sapiens;
-
pH 7.4, 37°C, cell-free enzyme extract
-
0.0055 - 0.0073
ethyl 5-hydroxy-2-phenylethyl-1H-indole-3-carboxylate
0.00013 - 0.00044
ethyl 5-hydroxy-2-phenylpropyl-1H-benzo[g]indole-3-carboxylate
0.00033 - 0.0028
ethyl 6-biphenyl-4-yl-(3-chlorobenzyl)-5-hydroxy-1H-indole-3-carboxylate
0.026
Eugenol
Homo sapiens;
-
non-competitive, reversible inhibitor, IC50: 0.026 mM
0.125
genistein
Homo sapiens;
-
pH 7.4, 27°C
0.0008
L-656,224
Homo sapiens;
-
i.e. 7-chloro-2-[(4-methoxyphenyl)-methyl]-3-methyl-5-propyl-4-benzofuranol, IC50: 0.0008 mM
0.0004
L-670,630
Homo sapiens;
-
IC50: 0.0004 mM
0.0003
L-689,065
Homo sapiens;
-
IC50: 0.0003 mM
0.00002
L-697,198
Homo sapiens;
-
IC50: 0.00002 mM
-
0.0015
L-702,701
Homo sapiens;
-
IC50: 0.0015 mM
-
0.000027
L-746,530
Homo sapiens;
-
IC50: 27 nM
0.00002
L705,302
Homo sapiens;
-
IC50: 0.00002 mM
-
0.00058 - 0.00086
methyl (4-[(5E)-5-(4-methoxybenzylidene)-4-oxo-4,5-dihydro-1,3-thiazol-2-yl]phenoxy)acetate
0.03
methyl 2-(allylamino)-1H-indole-3-carboxylate
Homo sapiens;
-
5-lipoxygenase inhibited in neutrophils; recombinant 5-lipoxygenase
0.0034 - 0.004
methyl 2-(benzylamino)-1H-indole-3-carboxylate
0.0069 - 0.0125
methyl 2-(diallylamino)-1H-indole-3-carboxylate
0.0098 - 0.0102
methyl 2-[(2-chlorophenyl)amino]-1H-indole-3-carboxylate
0.0035 - 0.0083
methyl 2-[(3-bromophenyl)amino]-1H-indole-3-carboxylate
0.0065 - 0.0081
methyl 2-[(3-chlorophenyl)amino]-1H-indole-3-carboxylate
0.0035 - 0.0055
methyl 2-[(3-chlorophenyl)amino]-5-chloro-1H-indole-3-carboxylate
0.0079 - 0.0134
methyl 2-[(3-fluorophenyl)amino]-1H-indole-3-carboxylate
0.0072 - 0.0098
methyl 2-[(4-chlorophenyl)amino]-1H-indole-3-carboxylate
0.004
miogadial
Homo sapiens;
-
potent inhibitor, IC50: 0.004 mM
0.0075
miogatrial
Homo sapiens;
-
potent inhibitor, IC50: 0.0075 mM
0.0032
MK-886
Homo sapiens;
-
37°C, whole blood assay
0.0011
MK886
Homo sapiens;
-
pH 7.4, 37°C
0.1
ML-3000
Homo sapiens;
-
above, 37°C, whole blood assay
0.05
N-(3,4-dimethoxyphenyl)-3,5-dinitrobenzamide
Homo sapiens;
-
pH 7.4, 37°C
0.002 - 0.01
N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)-1,3-benzodioxole-5-carboxamide
0.008 - 0.01
N-(3,5a,10-trimethyl-2-oxo-2,3,3a,4,5,5a,6,10,10a,10b-decahydrofuro[3',2':7,8]naphtho[2,3-d][1,3]thiazol-8-yl)cyclopentanecarboxamide
0.0144
N-(3-bromobenzyl)-3,5-dinitrobenzamide
Homo sapiens;
-
pH 7.4, 37°C
0.05
N-(3-bromophenyl)-3,5-dinitrobenzamide
Homo sapiens;
-
pH 7.4, 37°C
0.05
N-(3-chlorophenyl)-3,5-dinitrobenzamide
Homo sapiens;
-
pH 7.4, 37°C
0.000038 - 0.00016
N-(3-phenoxycinnamyl)-acetohydroxamic acid
0.0001
N-(4-chlorophenyl)-N-hydroxy-N'-(3-chlorophenyl)urea
Homo sapiens;
-
IC50: 0.0001 mM
0.0027
N-(4-methoxyphenyl)-3,5-dinitrobenzamide
Homo sapiens;
-
pH 7.4, 37°C
0.05
N-(biphenyl-3-yl)-3,5-dinitrobenzamide
Homo sapiens;
-
pH 7.4, 37°C
0.0009 - 0.01
N-(furan-2-ylmethyl)-2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide
0.05
N-(naphthalene-1-yl)-3,5-dinitrobenzamide
Homo sapiens;
-
pH 7.4, 37°C
0.00045
N-([4-[(2E)-3-(2,4-dichlorophenyl)prop-2-enoyl]phenyl]carbamoyl)-4-methylbenzenesulfonamide
Homo sapiens;
-
IC50: 0.00045 mM
0.05
N-3-tolyl-3,5-dinitrobenzamide
Homo sapiens;
-
pH 7.4, 37°C
-
0.01
N-cyclopentyl-2-[7-(2-methoxyethoxy)-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl]propanamide
Homo sapiens;
-
above, 37°C, intact polymorphonuclear leukocytes; above, 37°C, partially purified enzyme
0.00005 - 0.00016
N-hydroxy-N-[(2E)-3-(3-phenoxyphenyl)prop-2-en-1-yl]acetamide
0.0152
N-phenyl-3,5-dinitrobenzamide
Homo sapiens;
-
pH 7.4, 37°C
-
0.004 - 0.01
N-tert-butyl-2-(7-methoxy-5,8-dimethyl-1,2,3,4-tetrahydronaphthalen-2-yl)propanamide
0.0246
naphthalene-1-yl 3-nitrobenzoate
Homo sapiens;
-
pH 7.4, 37°C
0.00009
nordihydroguaiaretic acid
Homo sapiens;
-
pH 7.5, 37°C, assay method via fluorescence measurement
0.0158
phenyl 3,5-dinitrobenzoate
Homo sapiens;
-
pH 7.4, 37°C
0.0086
polygodial
Homo sapiens;
-
strong inhibitory activity, IC50: 0.0086 mM
0.00013
SC-756
Homo sapiens;
-
pH 7.5, 37°C, assay method via fluorescence measurement
0.02
sulindac sulfide
Homo sapiens;
-
pH and temperature not specified in the publication
0.0003
ZD 2138
Homo sapiens;
-
i.e. CAS: 140841-32-3, IC50: 0.0003 mM
0.00011 - 0.00012
ZD-2138
Homo sapiens;
-
pH 7.5, 37°C, dependent on assay method via fluorescence or UV measurement
0.00012 - 0.01
zileuton
0.00009
ZM 230,486
Homo sapiens;
-
IC50: 0.00009 mM
0.00074 - 0.00148
[1-(2-[[(2E)-3-phenylprop-2-enoyl]oxy]ethyl)-1H-1,2,3-triazol-4-yl]methyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
additional information
additional information
-